Skip to content
10-Q

Quarterly Report

CYCLERION THERAPEUTICS, INC. CYCN

0000950170-24-127116

← back to feed
Filed
Nov 14, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 9, 2024 2.71M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $2.87M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $7.57M
Stockholders Equity Q3 2024 · Sep 30, 2024 $8.2M
Stockholders Equity Q3 2024 · Jun 30, 2024 $8.78M
Stockholders Equity Q3 2024 · Mar 31, 2024 $9.92M
Stockholders Equity Q3 2024 · Dec 31, 2023 $11.29M
Stockholders Equity Q3 2024 · Sep 30, 2023 $12.87M
Stockholders Equity Q3 2024 · Jun 30, 2023 $5.15M
Stockholders Equity Q3 2024 · Mar 31, 2023 $3.93M
Stockholders Equity Q3 2024 · Dec 31, 2022 $10.45M
Current Liabilities Q3 2024 · Sep 30, 2024 $700K
Current Liabilities Q3 2024 · Dec 31, 2023 $2.09M
Current Assets Q3 2024 · Sep 30, 2024 $3.55M
Current Assets Q3 2024 · Dec 31, 2023 $8.02M
Total Assets Q3 2024 · Sep 30, 2024 $8.9M
Total Assets Q3 2024 · Dec 31, 2023 $13.37M
Shares Diluted Q3 2024 · Sep 30, 2023 2.79M sh
Shares Diluted Q3 2024 · Sep 30, 2023 2.3M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$19.7M
Eps Diluted Q3 2024 · Sep 30, 2023 $2.72
Eps Diluted Q3 2024 · Sep 30, 2023 −$1.55
Eps Basic restated Q3 2024 · Sep 30, 2023 $3.10
Eps Basic Q3 2024 · Sep 30, 2023 −$1.55
Sga Expense Q3 2024 · Sep 30, 2023 $2.13M
Sga Expense Q3 2024 · Sep 30, 2023 $6.36M
Rd Expense Q3 2024 · Sep 30, 2023 $580K
Rd Expense Q3 2024 · Sep 30, 2023 $1.49M
Net Income Q3 2024 · Sep 30, 2023 $7.57M
Net Income Q3 2024 · Sep 30, 2023 −$3.57M
Net Income Q3 2024 · Jun 30, 2023 −$4.18M
Net Income Q3 2024 · Mar 31, 2023 −$6.95M
Operating Income Q3 2024 · Sep 30, 2023 −$6.02M
Operating Income Q3 2024 · Sep 30, 2023 −$11.16M